5.76
price down icon1.54%   -0.09
after-market After Hours: 5.77 0.010 +0.17%
loading
Vir Biotechnology Inc stock is traded at $5.76, with a volume of 712.82K. It is down -1.54% in the last 24 hours and up +9.30% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$5.85
Open:
$5.79
24h Volume:
712.82K
Relative Volume:
0.55
Market Cap:
$796.25M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.4694
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+4.92%
1M Performance:
+9.30%
6M Performance:
-45.81%
1Y Performance:
-42.97%
1-Day Range:
Value
$5.70
$5.89
1-Week Range:
Value
$5.305
$5.98
52-Week Range:
Value
$4.32
$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name
Name
Vir Biotechnology Inc
Name
Phone
415-906-4324
Name
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Name
Employee
408
Name
Twitter
@Vir_Biotech
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
VIR's Discussions on Twitter

Compare VIR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VIR
Vir Biotechnology Inc
5.76 808.69M 62.04M -533.34M -473.07M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-29-24 Downgrade JP Morgan Overweight → Neutral
Sep-08-23 Downgrade BofA Securities Buy → Neutral
Mar-06-23 Upgrade JP Morgan Neutral → Overweight
Feb-21-23 Upgrade Goldman Neutral → Buy
Jan-27-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Sep-14-22 Initiated SVB Leerink Outperform
Sep-09-22 Initiated Morgan Stanley Underweight
Mar-03-22 Upgrade Robert W. Baird Underperform → Neutral
Dec-21-21 Downgrade Robert W. Baird Neutral → Underperform
Oct-25-21 Upgrade JP Morgan Underweight → Neutral
Sep-22-21 Downgrade Goldman Buy → Neutral
Jun-04-21 Resumed Robert W. Baird Neutral
Jan-27-21 Downgrade JP Morgan Neutral → Underweight
Jan-20-21 Reiterated H.C. Wainwright Buy
Oct-05-20 Initiated BofA Securities Buy
Sep-14-20 Upgrade Goldman Neutral → Buy
Sep-11-20 Upgrade JP Morgan Underweight → Neutral
Aug-20-20 Initiated Needham Buy
Mar-19-20 Downgrade JP Morgan Neutral → Underweight
Mar-13-20 Downgrade Goldman Buy → Neutral
Feb-27-20 Downgrade Robert W. Baird Neutral → Underperform
Feb-04-20 Downgrade JP Morgan Overweight → Neutral
Nov-14-19 Initiated Robert W. Baird Neutral
Nov-05-19 Initiated Barclays Overweight
Nov-05-19 Initiated Cowen Outperform
Nov-05-19 Initiated Goldman Buy
Nov-05-19 Initiated JP Morgan Overweight
View All

Vir Biotechnology Inc Stock (VIR) Latest News

pulisher
09:29 AM

Vir Biotechnology Begins Phase 1 Trial for VIR-5525 - TipRanks

09:29 AM
pulisher
08:18 AM

Vir Biotechnology doses first patient in EGFR-targeted cancer trial By Investing.com - Investing.com South Africa

08:18 AM
pulisher
08:05 AM

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors - Yahoo Finance

08:05 AM
pulisher
Jul 23, 2025

Vir Biotechnology Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Vir Biotechnology Inc. stock priceUnstoppable investment returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Vir Biotechnology: Hep B And Cancer Projects March On (NASDAQ:VIR) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

Have Insiders Sold Vir Biotechnology Shares Recently? - simplywall.st

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Vir Biotechnology Inc. stockRapidly expanding wealth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire

Jul 22, 2025
pulisher
Jul 22, 2025

Is Vir Biotechnology Inc. a good long term investmentSuperior investment outcomes - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

(VIR) Investment Analysis and Advice - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 17, 2025

Vir Biotechnology EVP Eisner sells $57k in stock By Investing.com - Investing.com Canada

Jul 17, 2025
pulisher
Jul 15, 2025

Biotech IPO For The Week Ahead - RTTNews

Jul 15, 2025
pulisher
Jul 11, 2025

Raymond James Initiates Vir Biotechnology(VIR.US) With Buy Rating, Announces Target Price $12 - 富途牛牛

Jul 11, 2025
pulisher
Jul 11, 2025

Where Vir Biotechnology Stands With Analysts - Benzinga

Jul 11, 2025
pulisher
Jul 11, 2025

Raymond James Initiates Vir Biotechnology at Outperform With $12 Price Target - MarketScreener

Jul 11, 2025
pulisher
Jul 10, 2025

Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - Yahoo Finance

Jul 10, 2025
pulisher
Jul 09, 2025

Unraveling Vir Biotechnology's 10.6% Spike: A Technical Deep Dive - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Unraveling Vir Biotechnology's 8.8% Surge: A Deep Dive - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

How to Take Advantage of moves in (VIR) - news.stocktradersdaily.com

Jul 08, 2025
pulisher
Jul 07, 2025

Vir Biotechnology Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution - simplywall.st

Jul 07, 2025
pulisher
Jul 02, 2025

Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jul 02, 2025
pulisher
Jun 25, 2025

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Jun 25, 2025
pulisher
Jun 17, 2025

Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 10, 2025

Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener

Jun 10, 2025
pulisher
Jun 05, 2025

(VIR) Trading Advice - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 03, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
May 29, 2025

Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks

May 29, 2025
pulisher
May 29, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace

May 29, 2025
pulisher
May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com

May 27, 2025
pulisher
May 26, 2025

Gilead Ready To Go After Hepatitis D Again - insights.citeline.com

May 26, 2025
pulisher
May 22, 2025

Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

May 22, 2025

Vir Biotechnology Inc Stock (VIR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Vir Biotechnology Inc Stock (VIR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Eisner Mark
EVP and Chief Medical Officer
Jul 17 '25
Sale
5.47
3,586
19,629
104,618
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):